Werewolf Therapeutics provides business update, highlights 2024 outlook

Werewolf Therapeutics provided a business update and outlined its strategic outlook and expected milestones for 2024. Werewolf outlined the following objectives as the Company’s strategic priorities for 2024: Prioritize development of wholly owned clinical-stage programs – present data updates from WTX-124 and WTX-330 while advancing their clinical development. Progress preclinical programs through IND-enabling work – demonstrate the breadth of Werewolf’s platform and portfolio opportunities. Apply PREDATOR platform for non-core opportunities and external innovation – leverage Werewolf’s validated technical capabilities, preclinical programs and opportunities in inflammatory diseases. Maintain disciplined spend – prudently allocate resources according to these priorities to optimize cash runway with continued focus on clinical development of lead programs. Based on these strategic priorities, Werewolf has provided the following guidance for 2024: WTX-124: In the first half of 2024, Werewolf plans to: Report updated interim data from the monotherapy dose-escalation arm of the Phase 1/1b study; Select a recommended dose for expansion and initiate monotherapy dose expansion arms; and Report initial data from the combination dose escalation cohorts of the Phase 1/1b study. WTX-330: Werewolf continues to progress the Phase 1 clinical trial evaluating WTX-330 as a monotherapy in patients with immunotherapy insensitive or resistant advanced or metastatic solid tumors or non-Hodgkin lymphoma. In 2024, Werewolf plans to report initial data from the Phase 1 clinical trial in the second quarter of 2024. Preclinical Portfolio: includes development candidates WTX-712 and WTX-518, INDUKINE molecules respectively targeting IL-21 and IL-18 for treatment of cancer, as well as numerous leads in discovery. Werewolf intends to progress these programs through IND-enabling work. In 2024, Werewolf plans to: Present preclinical data from WTX-712 in the first half of 2024. Present preclinical data from WTX-518 in the first half of 2024. Present preclinical data demonstrating the potential of INDUKINE molecules for inflammatory diseases by the fourth quarter of 2024. Werewolf now expects that its cash and equivalents will be sufficient to fund its operational expenses and capital expenditure requirements through at least the first quarter of 2025.